Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Biogen Inc. BIIB |
BLACKROCK INC BLK |
12,506,681 8.500% |
-2,140,070 (-14.61%) |
Filing History |
| 2025-01-10 5:34 pm Unchanged |
2025-01-10 | 13D | Sage Therapeutics, Inc. SAGE |
BIOGEN IDEC INC BIIB |
6,241,473 10.200% |
0 (Unchanged) |
Filing History |
| 2024-11-12 1:24 pm Unchanged |
2024-09-30 | 13G | Biogen Inc. BIIB |
The Vanguard Group | 16,677,806 11.440% |
0 (Unchanged) |
Filing History |
| 2024-11-07 4:48 pm Sale |
2024-10-30 | 13G | Denali Therapeutics Inc. DNLI |
BIOGEN IDEC INC BIIB |
7,155,243 4.970% |
-5,596,122 (-43.89%) |
Filing History |
| 2024-11-04 11:20 am Purchase |
2024-09-30 | 13G | Biogen Inc. BIIB |
The Vanguard Group | 16,677,806 11.440% |
2,156,464 (+14.85%) |
Filing History |
| 2024-10-16 12:11 pm Purchase |
2024-09-30 | 13G | Biogen Inc. BIIB |
STATE STREET CORP STT |
7,346,505 5.000% |
7,346,505 (New Position) |
Filing History |
| 2024-08-16 6:40 pm Sale |
2024-08-14 | 13G | Sangamo Therapeutics, Inc. SGMO |
BIOGEN IDEC INC BIIB |
3,250,000 1.600% |
-11,402,466 (-77.82%) |
Filing History |
| 2024-08-07 4:10 pm Purchase |
2024-07-31 | 13G | Biogen Inc. BIIB |
BLACKROCK INC BLK |
14,646,751 10.100% |
400,431 (+2.81%) |
Filing History |
| 2024-02-12 7:11 pm Sale |
2023-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
BIOGEN IDEC INC BIIB |
14,652,466 8.260% |
-9,767,691 (-40.00%) |
Filing History |
| 2024-02-12 7:07 pm Sale |
2023-12-31 | 13G | Denali Therapeutics Inc. DNLI |
BIOGEN IDEC INC BIIB |
12,751,365 9.230% |
-558,878 (-4.20%) |
Filing History |
| 2024-02-12 4:01 pm Purchase |
2023-12-31 | 13G | Biogen Inc. BIIB |
PRIMECAP MANAGEMENT CO | 16,264,481 11.220% |
563,905 (+3.59%) |
Filing History |
| 2024-02-12 11:21 am Purchase |
2024-01-31 | 13G | Biogen Inc. BIIB |
The Vanguard Group | 14,521,342 10.020% |
114,463 (+0.79%) |
Filing History |
| 2024-02-12 10:50 am Purchase |
2023-12-29 | 13G | Biogen Inc. BIIB |
The Vanguard Group | 14,406,879 9.940% |
2,430,256 (+20.29%) |
Filing History |
| 2024-01-24 2:27 pm Sale |
2023-12-31 | 13G | Biogen Inc. BIIB |
BLACKROCK INC BLK |
14,246,320 9.800% |
-13,817 (-0.10%) |
Filing History |
| 2023-09-28 4:38 pm Sale |
2023-09-26 | 13D | Reata Pharmaceuticals, Inc. RETA |
BIOGEN IDEC INC BIIB |
0 0.000% |
-8,936,791 (Position Closed) |
Filing History |
| 2023-08-07 5:21 pm Purchase |
2023-07-28 | 13D | Reata Pharmaceuticals, Inc. RETA |
BIOGEN IDEC INC BIIB |
8,936,791 23.400% |
8,936,791 (New Position) |
Filing History |
| 2023-02-09 4:01 pm Sale |
2022-12-31 | 13G | Biogen Inc. BIIB |
PRIMECAP MANAGEMENT CO | 15,700,576 10.900% |
-56,829 (-0.36%) |
Filing History |
| 2023-02-09 11:12 am Purchase |
2022-12-30 | 13G | Biogen Inc. BIIB |
The Vanguard Group | 11,976,623 8.320% |
439,324 (+3.81%) |
Filing History |
| 2023-01-24 1:56 pm Purchase |
2022-12-31 | 13G | Biogen Inc. BIIB |
BLACKROCK INC BLK |
14,260,137 9.900% |
523,183 (+3.81%) |
Filing History |
| 2022-03-07 2:51 pm Unchanged |
2021-12-31 | 13G | Biogen Inc. BIIB |
BLACKROCK INC BLK |
13,736,954 9.400% |
0 (Unchanged) |
Filing History |